Podocalyxin-like protein expression in primary colorectal cancer and synchronous lymph node metastases

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages 1-7

  Larsson, Anna H ^a   Nodin, Björn ^a   Syk, Ingvar ^a   Palmquist, Ingrid ^a   Uhlén, Mathias ^b   Eberhard, Jakob ^a   Jirström, Karin ^a  

^a LUND UNIVERSITY   (Sweden)

^b ALBANOVA UNIVERSITY CENTER   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882577601     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-109     Document Type: Article

References (19)

1. Kerjaschki D, Sharkey DJ, Farquhar MG. Identification and characterization of podocalyxin-the major sialoprotein of the renal glomerular epithelial cell. J Cell Biol 1984, 98(4):1591-1596. 10.1083/jcb.98.4.1591, 2113206, 6371025.
2. Miettinen A, Solin ML, Reivinen J, Juvonen E, Vaisanen R, Holthofer H. Podocalyxin in rat platelets and megakaryocytes. Am J Pathol 1999, 154(3):813-822. 10.1016/S0002-9440(10)65328-X, 1866405, 10079259.
3. McNagny KM, Pettersson I, Rossi F, Flamme I, Shevchenko A, Mann M, Graf T. Thrombomucin, a novel cell surface protein that defines thrombocytes and multipotent hematopoietic progenitors. J Cell Biol 1997, 138(6):1395-1407. 10.1083/jcb.138.6.1395, 2132552, 9298993.
4. Schopperle WM, Kershaw DB, DeWolf WC. Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin. Biochem Biophys Res Commun 2003, 300(2):285-290. 10.1016/S0006-291X(02)02844-9, 12504081.
5. Somasiri A, Nielsen JS, Makretsov N, McCoy ML, Prentice L, Gilks CB, Chia SK, Gelmon KA, Kershaw DB, Huntsman DG, et al. Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res 2004, 64(15):5068-5073. 10.1158/0008-5472.CAN-04-0240, 15289306.
6. Casey G, Neville PJ, Liu X, Plummer SJ, Cicek MS, Krumroy LM, Curran AP, McGreevy MR, Catalona WJ, Klein EA, et al. Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet 2006, 15(5):735-741. 10.1093/hmg/ddi487, 16434482.
7. Larsson A, Johansson ME, Wangefjord S, Gaber A, Nodin B, Kucharzewska P, Welinder C, Belting M, Eberhard J, Johnsson A, et al. Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer 2011, 105(5):666-672. 10.1038/bjc.2011.295, 3188928, 21829192.
8. Larsson A, Fridberg M, Gaber A, Nodin B, Leveen P, Jonsson G, Uhlen M, Birgisson H, Jirstrom K. Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer. BMC Cancer 2012, 12:282. 10.1186/1471-2407-12-282, 3492217, 22769594.
9. Cipollone JA, Graves ML, Kobel M, Kalloger SE, Poon T, Gilks CB, McNagny KM, Roskelley CD. The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. Clin Exp Metastasis 2012, 29(3):239-252. 10.1007/s10585-011-9446-0, 22262060.
10. Boman K, Larsson AH, Segersten U, Kuteeva E, Johannesson H, Nodin B, Eberhard J, Uhlen M, Malmstrom PU, Jirstrom K. Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer. Br J Cancer 2013, 108(11):2321-2328. 10.1038/bjc.2013.215, 23652315.
11. Dallas MR, Chen SH, Streppel MM, Sharma S, Maitra A, Konstantopoulos K. Sialofucosylated podocalyxin is a functional E- and L-selectin ligand expressed by metastatic pancreatic cancer cells. Am J Physiol Cell Physiol 2012, 303(6):C616-C624. 10.1152/ajpcell.00149.2012, 22814396.
12. Cheung HH, Davis AJ, Lee TL, Pang AL, Nagrani S, Rennert OM, Chan WY. Methylation of an intronic region regulates miR-199a in testicular tumor malignancy. Oncogene 2011, 30(31):3404-3415. 10.1038/onc.2011.60, 3117973, 21383689.
13. Laurinaviciene A, Dasevicius D, Ostapenko V, Jarmalaite S, Lazutka J, Laurinavicius A. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays. Diagn Pathol 2011, 6:87. 10.1186/1746-1596-6-87, 3191356, 21943197.
14. Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J, Skubitz AP, Metzger GJ, Schmechel SC. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol 2012, 7:42. 10.1186/1746-1596-7-42, 3379953, 22515559.
15. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001, 159(6):2249-2256. 10.1016/S0002-9440(10)63075-1, 1850582, 11733374.
16. Han CB, Li F, Ma JT, Zou HW. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest 2012, 30(10):741-747. 10.3109/07357907.2012.732159, 23075074.
17. Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S, Pierotti MA, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clinical cancer research: an official journal of the American Association for Cancer Research 2012, 18(6):1769-1776.
18. Falck AK, Ferno M, Bendahl PO, Ryden L. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?. World J Surg 2010, 34(7):1434-1441. 10.1007/s00268-010-0499-z, 20213203.
19. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370(9604):2020-2029. 10.1016/S0140-6736(07)61866-2, 18083404.